Sustainable Solutions,
Brighter Future

ABOUT AMELIO BIOMEDICAL

We are committed to developing innovative and bio-friendly solutions.

Amelio Biotech, established in 2016, is committed to developing products that are both life-friendly and efficient. The company name "Amelio" is derived from the English word "Ameliorate," meaning to improve.

The core technology of the company is amino acid supramolecular technology, aimed at creating a new generation of products combining amino acids and mineral elements. This technology is further applied and expanded within the life sciences industry.

Img
READ MORE

OUR SCIENCE

Metal Amino Click Synthesis

We create a new type of click chemistry. MACS is a unique and powerful atom-economy system which conjugates amino acids and target molecules as easily as building toy blocks.

MACS can be applied in several fields, including making small molecules that can kill cancer cells without harming healthy cells, delivering drugs through amino acid carriers, and making various health supplements.

READ MORE

EXPANDING THE HORIZONS OF MACS TECHNOLOGY

Medical Applications

Hemostatic Materials:

Rapid and effective blood clotting with excellent biocompatibility.

Cancer Drug Development:

Utilizing MACS technology, we have developed a new molecule, AMBG1, which has shown excellent inhibitory effects on various cancer cells.

AWARDS & RECOGNITION

Recognized on global innovation stages

Our MACS platform has gained international recognition across leading startup and innovation ecosystems — validating both its scientific strength and real-world potential.
Across global competitions, demo stages, and innovation showcases, MACS continues to receive strong recognition.

★

IMPACT
STARTUP

Recognized as an Impact Startup on one of the world’s leading innovation stages.

2025
★

GLOBAL
TOP 10

Recognized among the Global Top 10 for its innovation and market potential.

2024
View All Recognition
IN INTERNATIONAL MEDIA

From Taipei to Washington

Featured in a Los Angeles Times special supplement, this story reflects the growing international visibility of our innovation journey.

IN INTERNATIONAL MEDIA
Los Angeles
Times
SPECIAL SUPPLEMENT
Read the feature

Exhibitions & Media Highlights

Explore our latest exhibitions and media coverage showcasing innovation in biomedical technology.

Amelio at Smart City Summit & Expo
Taiwan

Amelio at Smart City Summit & Expo

Mar 17–20, 2026
Nangang Exhibition Center

Showcasing RealSeal ultra-fast hemostatic powder and our first pet-use product, expanding applications from emergency care to veterinary use.

Han Sheng Broadcasting
Han Sheng Radio

Han Sheng Radio Interview on MACS and RealSeal

23 DEC 2025

Amelio Biomedical shared insights into MACS technology and the clinical potential of RealSeal.

Commercial Times
Commercial Times

Featured in Commercial Times

18 DEC 2025

Highlighting RealSeal, our ultra-fast hemostatic powder developed on the MACS platform, with strong performance and biocompatibility.

Source: Commercial Times · Read full article →

Japan-Taiwan Innovation Summit
Global

Amelio at Web Summit 2025

28 NOV 2025
Lisbon, Portugal

Presenting MACS technology, application cases, and validation data to global investors and partners in Lisbon.

BIO Asia-Taiwan 2025
Global

Japan–Taiwan Innovation Summit

28 AUG 2025
Tokyo,Japan

Showcasing the MACS-based RealSeal solution in Tokyo, with Japanese partners on future medical and disaster-response applications.

Amelio at Meet Greater South 2025
Taiwan

Amelio at Meet Greater South 2025

Aug 22–23, 2025
Kaohsiung Exhibition Center

Showcasing RealSeal for high-risk bleeding scenarios, powered by MACS technology for fast, clean, and biocompatible hemostasis.

BIO Asia-Taiwan 2025 Demo
Taiwan

RealSeal at BIO Asia–Taiwan 2025

26 JUL 2025
Nangang Exhibition Center

Presented at the NHRI pavilion, with MACS applications in hemostasis and oncology also featured on the main stage.

NBRP Demo Day
Taiwan

RealSeal at BIO Asia–Taiwan

24 JUL 2025
Nangang Exhibition Center

Demonstrating fast hemostasis, low toxicity, and early validation data at the NHRI pavilion.

NBRP Demo Day
Taiwan

RealSeal at NBRP Demo Day

24 JUL 2025
Nangang Exhibition Center

A MACS-based hemostatic solution designed for rapid bleeding control in high-risk scenarios.

Los Angeles Times
Los Angeles Times

From Taipei to Washington

9 Oct 2025

Featured in a Los Angeles Times special supplement highlighting Taiwan’s biomedical innovation.

Source: Los Angeles Times · Read full article →

Founded with the vision of creating a better future through innovative agricultural solutions, Amelio Biomedical has rapidly advanced in developing our unique MACS technology. We have partnered with leading organizations and secur

The Amelio Biomedical R&D team continuously drives innovation and application of MACS technology. We collaborate with international companies and institutions to promote global application. For more information or collaboration opportunities, please contact us.

CONTACT US